Columbia Care Announces Collaboration with IPS Specials and Grow Biotech to Import BeneCeed™ Tablets to the United Kingdom for Clinical Study

BeneCeed poised to become the first formulated botanical cannabinoid investigational medicinal product imported from the US approved by the MHRA

Collaboration represents first step in Columbia Care’s efforts to conduct global clinical trials with its proprietary cannabis-based medicines

NEW YORK — Columbia Care Inc. (NEO: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest fully integrated operators in the global medical cannabis industry with licenses across the US and EU, announced today a collaboration with IPS Specials, an experienced compounding pharmaceutical manufacturer, importer and distributor of unlicensed “specials” and licensed medicines in the UK and the rest of the EU, and Grow Biotech, a company bridging the gap between existing cannabis medicines and accepted pharmaceutical standards, to import Columbia Care’s proprietary, broad-spectrum high-cannabidiol (CBD) BeneCeed tablets as a potential investigational medicinal product (IMP) to the United Kingdom (UK) for clinical study. Pending approval by

... read more at: https://business.financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/columbia-care-announces-collaboration-with-ips-specials-and-grow-biotech-to-import-beneceed-tablets-to-the-united-kingdom-for-clinical-study

by